Advisors Preferred’s ResMed RMD Stock Holding History

Advisors Preferred’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,809	Closed	-$999K	–	223
2021 Q3	$999K	Buy	+3,809	New	+$1.04M	0.14%	55
2021 Q1	–	Sell	-2,871	Closed	-$609K	–	201
2020 Q4	$609K	Buy	+2,871	New	+$572K	0.11%	101
2017 Q2	–	Sell	-3,618	Closed	-$260	–	273
2017 Q1	$260	Buy	+3,618	New	+$250K	0.14%	64
2016 Q2	–	Sell	-175	Closed	-$10K	–	287
2016 Q1	$10K	Buy	+175	New	+$9.9K	0.01%	161

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Advisors Preferred's RMD Position: Q4 2021 in Review

Advisors Preferred sold out of ResMed (RMD) in Q4 2021, closing a stake of 3,809 shares — an estimated $999K sold.

Advisors Preferred first reported a position in RMD in Q1 2016 and held it in 4 quarters. The position peaked at $999K in Q3 2021. 723 funds tracked by Wall St. Rank hold RMD as of Q4 2021.

Advisors Preferred reported no remaining ResMed position as of Q4 2021 after selling out during the quarter.
Advisors Preferred sold 3,809 ResMed shares in Q4 2021, an estimated $999K.
Advisors Preferred first reported a position in ResMed in Q1 2016 and held it in 4 quarters.
Advisors Preferred's ResMed position peaked at $999K in Q3 2021.
723 funds tracked by Wall St. Rank held ResMed as of Q4 2021.

Based on Advisors Preferred's 13F filing for Q4 2021, filed 7 Feb 2022.